Effect of HMGN2 on proliferation and apoptosis of MCF-7 breast cancer cells

We investigated the effect of high mobility group protein N2 (HMGN2) on the proliferation and apoptosis of the human MCF-7 breast cancer cell line, and its effect on tumor growth in a subcutaneous heterotopic transplantation tumor model of breast cancer. The cell viability assay was used to verify the effect of the recombinant human HMGN2 on MCF-7 cell proliferation. The Transwell chamber assay was used to verify the effect of HMGN2 on MCF-7 cell migration. Flow cytometry and Hoechst staining were used to detect the effect of HMGN2 on MCF-7 cell apoptosis. MCF-7 was injected to establish a subcutaneous heterotopic transplantation tumor model of breast cancer in nude mice. The size, weight and volume of tumor in each group were compared after the administration of different concentrations of HMGN2 solution around the tumor tissue at day 1, 3, 5 and 7. The tumor tissue was removed and cut into sections, and the apoptotic cells in tumors of nude mice were detected by a TUNEL kit. The CCK-8 assay showed that HMGN2 at different concentrations inhibited the proliferation of the MCF-7 breast cancer cells, and the proliferation of MCF-7 cells were significantly inhibited when the concentration of HMGN2 reached 3 µg/ml (P<0.01). The Transwell chamber assay showed that 3 µg/ml of HMGN2 significantly decreased the migration capacity of MCF-7 cells (P<0.01). Flow cytometry and Hoechst staining showed that 3 µg/ml of HMGN2 significantly increased apoptosis of MCF-7 cells (P<0.01). After the nude mouse model of breast cancer was established, HMGN2 at different concentrations was injected around the tumor tissue at day 1, 3, 5 and 7. We demonstrated that the growth of breast cancer was significantly inhibited when the concentration of HMGN2 reached 15 µg/ml. TUNEL staining showed that the number of apoptotic cells in the 15 µg/ml dose group was significantly higher than that in the control group (P<0.01). Therefore, in vitro and in vivo experiments proved that recombinant human HMGN2 could significantly inhibit the proliferation and migration of breast cancer cells, which increased the apoptosis of breast cancer cells and exerted anti-breast cancer effects, which enriched our understanding of the biological roles of HMGN2.

[1]  S. Tate,et al.  Nucleosome structural changes induced by binding of non-histone chromosomal proteins HMGN1 and HMGN2☆ , 2013, FEBS open bio.

[2]  J. Lei,et al.  Mammary Ductal Environment Is Necessary for Faithful Maintenance of Estrogen Signaling in ER⁺ Breast Cancer. , 2016, Cancer cell.

[3]  Y. Ishihama,et al.  Ectopic expression of Hmgn2 antagonizes mouse erythroid differentiation in vitro , 2012, Cell biology international.

[4]  P. Cin,et al.  Involvement of the HMGI(Y) gene in a microfollicular adenoma of the thyroid , 1999, Genes, chromosomes & cancer.

[5]  Qianming Chen,et al.  HMGN2 protein inhibits the growth of infected T24 cells in vitro. , 2014, Journal of cancer research and therapeutics.

[6]  M. Bustin,et al.  The nucleosome‐binding protein HMGN2 modulates global genome repair , 2009, The FEBS journal.

[7]  C. Musselman,et al.  Methyl fingerprinting of the nucleosome reveals the molecular mechanism of high-mobility group nucleosomal-2 (HMGN2) association , 2011, Proceedings of the National Academy of Sciences.

[8]  M. K. Swamy,et al.  Synthesis, Characterization and in Vitro Evaluation of Manganese Ferrite (MnFe2O4) Nanoparticles for Their Biocompatibility with Murine Breast Cancer Cells (4T1) , 2016, Molecules.

[9]  Xin Hu,et al.  Elevated expression of RNA methyltransferase BCDIN3D predicts poor prognosis in breast cancer , 2016, Oncotarget.

[10]  L. Churilov,et al.  Nuclear protein HMGN2 attenuates pyocyanin‐induced oxidative stress via Nrf2 signaling and inhibits Pseudomonas aeruginosa internalization in A549 cells , 2017, Free radical biology & medicine.

[11]  J. Licht,et al.  Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells* , 2016, The Journal of Biological Chemistry.

[12]  Hiroshi I. Suzuki,et al.  An Integrated Expression Profiling Reveals Target Genes of TGF-β and TNF-α Possibly Mediated by MicroRNAs in Lung Cancer Cells , 2013, PloS one.

[13]  K. Hemminki,et al.  Functional germline variants in driver genes of breast cancer , 2017, Cancer Causes & Control.

[14]  Guixia Wu,et al.  High-mobility group protein N2 (HMGN2) inhibited the internalization of Klebsiella pneumoniae into cultured bladder epithelial cells. , 2011, Acta biochimica et biophysica Sinica.

[15]  D. Melgaard.  What is the effect of treating secondary lymphedema after breast cancer with complete decongestive physiotherapy when the bandage is replaced with Kinesio Textape? – A pilot study , 2016, Physiotherapy theory and practice.

[16]  Yalun Li,et al.  False-negative Frozen Section of Sentinel Lymph Node Biopsy in a Chinese Population with Breast Cancer. , 2016, Anticancer research.

[17]  K. Enokido,et al.  Digital volumetric measurement of mammographic density and the risk of overlooking cancer in Japanese women , 2017, Breast Cancer.

[18]  Jin-Hyun Ahn,et al.  High Mobility Group Nucleosomal Binding Domain 2 (HMGN2) SUMOylation by the SUMO E3 Ligase PIAS1 Decreases the Binding Affinity to Nucleosome Core Particles* , 2014, The Journal of Biological Chemistry.

[19]  Qianming Chen,et al.  Nucleosome-binding protein HMGN2 exhibits antitumor activity in oral squamous cell carcinoma , 2013, Oncology letters.